NVIVQ (NVIVQ)
OTCMKTS: NVIVQ · Delayed Price · USD
0.372
+0.012 (3.44%)
Apr 23, 2024, 3:57 PM EDT - Market closed
Company Description
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States.
The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI).
It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment.
The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
NVIVQ
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Richard Toselli |
Contact Details
Address: One Kendall Square, Building 1400 East 4th Floor Cambridge, Massachusetts 02139 United States | |
| Phone | 617-863-5524 |
Stock Details
| Ticker Symbol | NVIVQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001292519 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Richard M. Toselli M.D. | President, Chief Executive Officer, Chief Medical Officer and Director |
| Richard C. Christopher | Chief Financial Officer and Treasurer |
| Heather M. Hamel J.D. | Chief Legal Officer and General Counsel |
| Dr. Robert S. Langer Jr., Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Joseph Philip Vacanti M.D. | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2024 | 25-NSE | Filing |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | 8-K | Current Report |
| Feb 1, 2024 | 8-K | Current Report |
| Jan 3, 2024 | 8-K | Current Report |
| Dec 5, 2023 | ARS | Filing |
| Dec 5, 2023 | DEF 14A | Other definitive proxy statements |
| Dec 1, 2023 | 8-K | Current Report |